Skip to main content
. 2014 Jul 2;171(18):4247–4254. doi: 10.1111/bph.12771

Table 1.

Clinical characteristics of the random sample of drugs included in our analysis (n = 47)

Indication n Furthest stage of development (%) FDA approval (%)
Phase 2 Phase 3
Cancer 19 9 (47%) 9 (47%) 5 (26%)
Cardiovascular 9 3 (33%) 5 (56%) 2 (22%)
Infection 9 2 (22%) 7 (78%) 3 (33%)
Neurological 4 0 2 (50%) 1 (25%)
Sepsis 3 3 (100%) 0 0
Pain 2 0 2 (100%) 0
Diabetes 1 1 (100%) 0 0
Total 47 18 (38%) 25 (53%) 11 (23%)